151 related articles for article (PubMed ID: 35278773)
1. A fragment-based structural analysis of MMP-2 inhibitors in search of meaningful structural fragments.
Banerjee S; Amin SA; Jha T
Comput Biol Med; 2022 May; 144():105360. PubMed ID: 35278773
[TBL] [Abstract][Full Text] [Related]
2. A fragment-based exploration of diverse MMP-9 inhibitors through classification-dependent structural assessment.
Baidya SK; Banerjee S; Ghosh B; Jha T; Adhikari N
J Mol Graph Model; 2024 Jan; 126():108671. PubMed ID: 37976979
[TBL] [Abstract][Full Text] [Related]
3. A robust classification-dependent multi-molecular modelling study on some biphenyl sulphonamide based MMP-8 inhibitors.
Guti S; Baidya SK; Banerjee S; Adhikari N; Jha T
SAR QSAR Environ Res; 2021 Oct; 32(10):835-861. PubMed ID: 34587852
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
[TBL] [Abstract][Full Text] [Related]
5. Exploration of structural alerts and fingerprints for novel anticancer therapeutics: a robust classification-QSAR dependent structural analysis of drug-like MMP-9 inhibitors.
Banerjee S; Baidya SK; Ghosh B; Jha T; Adhikari N
SAR QSAR Environ Res; 2023 Apr; 34(4):299-319. PubMed ID: 37170840
[TBL] [Abstract][Full Text] [Related]
6. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
[TBL] [Abstract][Full Text] [Related]
7. Identification of Non-Zinc Binding Inhibitors of MMP-2 Through Virtual Screening and Subsequent Rescoring.
Shamsara J
Drug Res (Stuttg); 2018 Sep; 68(9):529-535. PubMed ID: 29614516
[TBL] [Abstract][Full Text] [Related]
8. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
Rashid ZA; Bardaweel SK
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
[TBL] [Abstract][Full Text] [Related]
9. Insight into the structural requirement of aryl sulphonamide based gelatinases (MMP-2 and MMP-9) inhibitors - Part I: 2D-QSAR, 3D-QSAR topomer CoMFA and Naïve Bayes studies - First report of 3D-QSAR Topomer CoMFA analysis for MMP-9 inhibitors and jointly inhibitors of gelatinases together.
Das S; Amin SA; Jha T
SAR QSAR Environ Res; 2021 Aug; 32(8):655-687. PubMed ID: 34355614
[TBL] [Abstract][Full Text] [Related]
10. Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity.
Solomon A; Rosenblum G; Gonzales PE; Leonard JD; Mobashery S; Milla ME; Sagi I
J Biol Chem; 2004 Jul; 279(30):31646-54. PubMed ID: 15102849
[TBL] [Abstract][Full Text] [Related]
11. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
[TBL] [Abstract][Full Text] [Related]
12. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2).
Rosenblum G; Meroueh SO; Kleifeld O; Brown S; Singson SP; Fridman R; Mobashery S; Sagi I
J Biol Chem; 2003 Jul; 278(29):27009-15. PubMed ID: 12679334
[TBL] [Abstract][Full Text] [Related]
14. Functional mimetic peptide discovery isolated by phage display interacts selectively to fibronectin domain and inhibits gelatinase.
Shoari A; Rasaee MJ; Kanavi MR; Daraei B
J Cell Biochem; 2019 Dec; 120(12):19699-19711. PubMed ID: 31270859
[TBL] [Abstract][Full Text] [Related]
15. Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.
Remacle AG; Cieplak P; Nam DH; Shiryaev SA; Ge X; Strongin AY
Oncotarget; 2017 Jan; 8(2):2781-2799. PubMed ID: 27835863
[TBL] [Abstract][Full Text] [Related]
16. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
[TBL] [Abstract][Full Text] [Related]
17. Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors.
Laghezza A; Luisi G; Caradonna A; Di Pizio A; Piemontese L; Loiodice F; Agamennone M; Tortorella P
Bioorg Med Chem; 2020 Feb; 28(3):115257. PubMed ID: 31874775
[TBL] [Abstract][Full Text] [Related]
18. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
Xie XW; Wan RZ; Liu ZP
ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
[TBL] [Abstract][Full Text] [Related]
19. Chemically modified tetracyclines as inhibitors of MMP-2 matrix metalloproteinase: a molecular and structural study.
Marcial BL; Sousa SF; Barbosa IL; Dos Santos HF; Ramos MJ
J Phys Chem B; 2012 Nov; 116(46):13644-54. PubMed ID: 23121406
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.
Choi JY; Fuerst R; Knapinska AM; Taylor AB; Smith L; Cao X; Hart PJ; Fields GB; Roush WR
J Med Chem; 2017 Jul; 60(13):5816-5825. PubMed ID: 28653849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
